Gout – Landscape & Forecast – Disease Landscape & Forecast (G7)

Gout, a type of inflammatory arthritis, results from the persistent elevation of serum uric acid (sUA) levels. This condition is characterized by sudden and severe gout flares, which cause significant discomfort. Chronic gout is primarily managed with urate-lowering therapies (ULTs), including xanthine oxidase inhibitors (XOIs), uricosuric agents, and uricase analogues. Acute gout flares are treated with nonsteroidal anti-inflammatory drugs (NSAIDs), colchicine, corticosteroids, and anti-IL-1 agents, which also serve as prophylactic measures while initiating ULTs to prevent flares. Despite existing treatments, there remains a considerable need for safer, less frequently dosed agents to treat chronic refractory gout. The gout therapy market is projected to expand over the 2025-2035 forecast period, driven by an increasing number of diagnosed gout cases and the introduction of novel drugs such as Sobi Therapeutics’ NASP (SEL-212), Atom Therapeutics’ lingolinurad (ABP-671), Arthrosi Therapeutics’ pozdeutinurad (AR882), Crystalys Therapeutics’ dotinurad, and Olatec Therapeutics’ dapansutrile.

QUESTIONS ANSWERED

• What are the incidence and prevalence of gout in the major pharmaceutical markets under study?
• How is gout currently treated? What are experts’ opinions of Amgen’s Krystexxa as a treatment for chronic refractory gout?
• What is the commercial potential of emerging therapies? How do leaders in the field of gout management rate these drug candidates?
• How will the gout therapy market evolve over the next 10 years?

CONTENT HIGHLIGHTS

• Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.
• Primary research: Country-specific interviews with thought-leading rheumatologists. Supported by survey data collected for this and other Clarivate research.
• Epidemiology: Incidence and prevalence of diagnosed gout population by country and drug-treated rates.
• Drug treatments: Coverage of key current and emerging therapies.
• Market forecast features: 10-year, annualized, drug-level sales and patient share of key gout therapies through 2035, segmented by brands / generics.

PRODUCT DESCRIPTION

Disease Landscape & Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:

• Optimize your long-term disease and development strategy.
• Quantify market potential for your pipeline assets and those of your competitors.
• Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.
• Gauge the commercial outlook and impact of key market events.